QUALITY TIME
SECURED

Breakthrough therapy that can eliminate mitral regurgitation in select patients

Tendyne™ Transcatheter mitral valve implantation (TMVI) is a breakthrough technology that offers select patients who have symptomatic, significant mitral regurgitation (≥ grade 3), a new option for safe and effective valve replacement. Tendyne TMVI is less invasive than conventional mitral valve surgery and provides symptom relief and quality of life improvement by eliminating MR.

• Complete MR elimination in 99% of patients at 30 days¹
• Sustained MR elimination in 93% of patients at 2 years¹
• 96% technical success rate in minimally invasive procedure^1,*
• Excellent safety profile¹
• Distinct product design enabling repositioning and full retrievability intraprocedurally
• Significant improvement in symptom and quality-of-life measures¹
   

*Technical success per MVARC.